These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 19841190)

  • 1. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
    Basler M; Lauer C; Beck U; Groettrup M
    J Immunol; 2009 Nov; 183(10):6145-50. PubMed ID: 19841190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.
    von Herrath MG; Coon B; Lewicki H; Mazarguil H; Gairin JE; Oldstone MB
    J Immunol; 1998 Nov; 161(9):5087-96. PubMed ID: 9794447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of the cytotoxic T lymphocyte response to lymphocytic choriomeningitis virus in mice subjected to chronic social stress.
    Sommershof A; Basler M; Riether C; Engler H; Groettrup M
    Brain Behav Immun; 2011 Feb; 25(2):340-8. PubMed ID: 20974245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.
    Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Shimizu K; Sato S
    J Leukoc Biol; 2010 Jul; 88(1):117-22. PubMed ID: 20418448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
    Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
    Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protracted course of lymphocytic choriomeningitis virus WE infection in early life: induction but limited expansion of CD8+ effector T cells and absence of memory CD8+ T cells.
    Belnoue E; Fontannaz-Bozzotti P; Grillet S; Lambert PH; Siegrist CA
    J Virol; 2007 Jul; 81(14):7338-50. PubMed ID: 17494081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
    Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of human respiratory syncytial virus infected Balb/C mice with the proteasome inhibitor bortezomib (Velcade, PS-341) results in increased inflammation and mortality.
    Lupfer C; Patton KM; Pastey MK
    Toxicology; 2010 Jan; 268(1-2):25-30. PubMed ID: 19931343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of a high frequency of virus-specific CD4+ T cells during acute infection with lymphocytic choriomeningitis virus.
    Varga SM; Welsh RM
    J Immunol; 1998 Oct; 161(7):3215-8. PubMed ID: 9759834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
    [No Abstract]   [Full Text] [Related]  

  • 13. Priming of CD8+ T cell responses by pathogens typically depends on CD70-mediated interactions with dendritic cells.
    Schildknecht A; Miescher I; Yagita H; van den Broek M
    Eur J Immunol; 2007 Mar; 37(3):716-28. PubMed ID: 17295392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
    Lang VR; Mielenz D; Neubert K; Böhm C; Schett G; Jäck HM; Voll RE; Meister S
    J Immunol; 2010 Nov; 185(9):5637-47. PubMed ID: 20921528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
    Wolter KG; Verhaegen M; Fernández Y; Nikolovska-Coleska Z; Riblett M; de la Vega CM; Wang S; Soengas MS
    Cell Death Differ; 2007 Sep; 14(9):1605-16. PubMed ID: 17541428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes.
    Basler M; Groettrup M
    Eur J Immunol; 2007 Apr; 37(4):896-904. PubMed ID: 17357105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.
    Anan A; Baskin-Bey ES; Isomoto H; Mott JL; Bronk SF; Albrecht JH; Gores GJ
    Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G709-16. PubMed ID: 16798723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury.
    Huber JM; Tagwerker A; Heininger D; Mayer G; Rosenkranz AR; Eller K
    Am J Physiol Renal Physiol; 2009 Aug; 297(2):F451-60. PubMed ID: 19458122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.